Worker at Bauer's Candies facility in Kentucky tested positive for hepatitis A.
Evidence convincing that universal prenatal screening reduces perinatal transmission of HBV.
The Advisory Committee on Immunization Practices Hepatitis Vaccines Work Group has updated recommendations for hepatitis A vaccination for PEP and PrEP.
Second study shows no significant difference in patients' survival based on donor BMI.
Those with HCV genotype 1 with recent injection drug use and/or current opioid substitution therapy, paritaprevir/ritonavir, ombitasvir, and dasabuvir with/without ribavirin is effective.
Patients with chronic HCV undergoing short-term glecaprevir and pibrentasvir treatment show improved cardiovascular and metabolic extrahepatic manifestations.
Findings based on birth cohort, risk-based testing vs opt-out testing in prison system.
Adherence to the American Association for the Study of Liver Diseases criteria for evaluation and treatment of chronic HBV infection was found to be poor in all practice settings assessed.
Investigators aimed to determine rates and predictors of cirrhosis and cirrhosis-related complications in patients with chronic hepatitis B infection.
There is a lack of consensus among experts and professional organizations whether HCV screening in pregnant women should be risk based or universal.
Overall, 1.7 and 1.0% of all US adults HCV antibody-positive and HCV RNA-positive.
The introduction of DAAs has caused a significant reduction in the percentage of liver transplant recipients for HCV who are viremic after surgery.
Universal 1-time screening for chronic HCV infection is cost-effective compared with no screening or with birth cohort-based screening alone.
The American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) released updates guidelines for treating hepatitis C infection.
The study authors searched MEDLINE from inception through July 2018 to obtain relevant cohort studies and randomized trials assessing HBVr incidence secondary to pharmaceutical agents.
One of the goals of the US Department of Health and Human Services National Viral Hepatitis Action Plan is to eliminate mother-to-infant transmission of HCV infection.
Investigators examined treatment response of sofosbuvir-based DAA in patients with chronic hepatitis C with compensated liver cirrhosis in a community care setting.
Analysis of 2 phase 3 clinical trials evaluating the safety/efficacy of glecaprevir/pibrentasvir in people with HCV coinfected with HIV-1 found an overall sustained virologic response of 98% at week 12 of treatment in those with or without cirrhosis.
The first human case of a strain of hepatitis E previously found only in rats was diagnosed in a Hong Kong man who received a liver transplant in May 2017.
Inspection at the VIP Spa in Albuquerque detected practices that might spread HIV or hepatitis B and C.
Curing HCV infection with direct-acting antiretrovirals is associated with regression of liver fibrosis for most patients.
The researchers found a significant difference in mean time to direct-acting antiviral agent treatment among participants with public insurance payers compared with private insurance payers.
The neuropsychiatric symptoms associated with HCV infection are likely caused by the body's response to the virus' effects on brain function.
A robust anamnestic response was mounted in most adolescents when challenged with a dose of monovalent HBV vaccine.
Direct-acting antivirals are safe and effective in African-American patients with chronic HCV.
There is an opportunity to improve HCV treatment rates for people who inject drugs by integrating DAA therapy into current models of community-based addiction.
All 20 recipients experienced HCV cure, good quality of life, excellent renal function.
Drop in median price of WHO-prequalified generic tenofovir from 208 to 32 from 2004 to 2016
Investigators added hepatitis C virus and HIV screening tests to standard trauma activation laboratory orders.
Coordinated treatment programs may improve treatment outcomes in patients with hepatitis C infection.